Article    Table of Contents                    Full Text of this article Free    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    McNamara, R. L.    Bass, E. B.    Related Articles in PubMed    PubMed Citation    PubMed

CLINICAL GUIDELINES

Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography

Robert L. McNamara, MD, MHS; Leonardo J. Tamariz, MD, MPH; Jodi B. Segal, MD, MPH; and Eric B. Bass, MD, MPH

16 December 2003 | Volume 139 Issue 12 | Pages 1018-1033

Purpose: This review summarizes the available evidence regarding the efficacy of medications used for ventricular rate control, stroke prevention, acute conversion, and maintenance of sinus rhythm, as well as the efficacy of electrical cardioversion and the use of echocardiography in patients with atrial fibrillation.

Data Sources: The Cochrane Collaboration's database of controlled clinical trials and MEDLINE.

Study Selection: Primarily randomized, controlled trials of medications.

Data Extraction: Paired reviewers obtained data on efficacy and safety. Strength of evidence was assessed.

Data Synthesis: Recent clinical trial results showed that most patients with atrial fibrillation have similar outcomes with strategies for controlling ventricular rate compared with strategies for restoring sinus rhythm. For efficacy of primary stroke prevention, compared with placebo, evidence was strong for warfarin and suggestive for aspirin. The evidence for an increased risk for major bleeding was suggestive for warfarin and inconclusive for aspirin. For ventricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to digoxin and placebo, particularly during exercise. For efficacy of acute conversion, compared with placebo, evidence was strong for ibutilide, flecainide, dofetilide, propafenone, amiodarone, and quinidine. For efficacy of maintenance of sinus rhythm after conversion from atrial fibrillation, evidence was strong for amiodarone, propafenone, disopyramide, and sotalol. Echocardiography was found to be useful in estimating risk for thromboembolism and potentially useful in estimating likelihood of successful cardioversion and maintenance.

Conclusions: For several key questions in the pharmacologic management of atrial fibrillation, strong evidence exists to support 1 or more treatment options.

Author and Article Information

From Yale University School of Medicine, New Haven, Connecticut, and Johns Hopkins University, Baltimore, Maryland.

Disclaimer: The authors are responsible for the content of this article, including any treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Acknowledgments: The authors thank Karen Robinson and Drs. Marlene Miller, Steve Goodman, and Neil Powe for their valuable contribution to the Evidence-based Report on the Management of Atrial Fibrillation.

Grant Support: Portions of this background paper were drawn from a review conducted by the Johns Hopkins Evidence-based Practice Center through Contract No. 290-97-0006 from the Agency for Healthcare Research and Quality, Rockville, MD. Dr. Tamariz was supported by a training grant in behavioral research in heart and vascular diseases from the National Heart, Lung, and Blood Institute (T32HL07180).

Potential Financial Conflicts of Interest:Consultancies: R.L. McNamara (Aventis, EU3); Grants received: L.J. Tamariz (National Heart, Lung, and Blood Institute).

Requests for Single Reprints: Robert L. McNamara, MD, MHS, Cardiovascular Section, Yale University, 333 Cedar Street, 316 FMP, P.O. Box 208017, New Haven, CT 06520-8017; e-mail, robert.mcnamara{at}yale.edu.

Current Author Addresses: Dr. McNamara: Cardiovascular Section, Yale University, 333 Cedar Street, 315A FMP, P.O. Box 208017, New Haven, CT 06520-8017.

Dr. Tamariz: 2024 East Monument Street, Room 2-516, Baltimore, MD 21205.

Dr. Segal: 720 Rutland Avenue, Ross #1025, Baltimore, MD 21205.

Dr. Bass: 1830 East Monument Street, Room 8068, Baltimore, MD 21287.

Related articles in Annals:

Clinical Guidelines
Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians
Vincenza Snow, Kevin B. Weiss, Michael LeFevre, Robert McNamara, Eric Bass, Lee A. Green, Keith Michl, Douglas K. Owens, Jeffrey Susman, Deborah I. Allen, Christel Mottur-Pilson, AND the Joint AAFP/ACP Panel on Atrial Fibrillation

Annals 2003 139: 1009-1017. [ABSTRACT][SUMMARY][Full Text]  

Summaries for Patients
Management of Newly Detected Atrial Fibrillation: Recommendations from the American College of Physicians and the American Academy of Family Physicians

Annals 2003 139: I-32. [Full Text]  

This article has been cited by other articles:

				F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode Europace, January 1, 2008; 10(1): 21 - 27. [Abstract] [Full Text] [PDF]

				C. Varounis, N. Dagres, T. Maounis, D. Panagiotakos, and D. V. Cokkinos Atrial premature complexes and heart rate have prognostic significance in 1-month atrial fibrillation recurrence after electrical cardioversion Europace, August 1, 2007; 9(8): 633 - 637. [Abstract] [Full Text] [PDF]

				N Sulke, F Sayers, G Y H Lip, and on behalf of the Guideline Development Group for t Rhythm control and cardioversion Heart, January 1, 2007; 93(1): 29 - 34. [Full Text] [PDF]

				P Korantzopoulos, T M Kolettis, A Papathanasiou, K K Naka, P Kolios, I Leontaridis, A Draganigos, C S Katsouras, and J A Goudevenos Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation Heart, May 1, 2006; 92(5): 631 - 634. [Abstract] [Full Text] [PDF]

				O Viktorsdottir, A Henriksdottir, and D O Arnar Ibutilide for treatment of atrial fibrillation in the emergency department Emerg. Med. J., February 1, 2006; 23(2): 133 - 134. [Abstract] [Full Text] [PDF]

				A. Squizzato, V.E.A. Gerdes, D.P.M. Brandjes, H.R. Buller, and J. Stam Thyroid Diseases and Cerebrovascular Disease Stroke, October 1, 2005; 36(10): 2302 - 2310. [Abstract] [Full Text] [PDF]

				G. Di Salvo, P. Caso, R. Lo Piccolo, A. Fusco, A. R. Martiniello, M. G. Russo, A. D'Onofrio, S. Severino, P. Calabro, G. Pacileo, et al. Atrial Myocardial Deformation Properties Predict Maintenance of Sinus Rhythm After External Cardioversion of Recent-Onset Lone Atrial Fibrillation: A Color Doppler Myocardial Imaging and Transthoracic and Transesophageal Echocardiographic Study Circulation, July 19, 2005; 112(3): 387 - 395. [Abstract] [Full Text] [PDF]

				B. N. Singh, S. N. Singh, D. J. Reda, X. C. Tang, B. Lopez, C. L. Harris, R. D. Fletcher, S. C. Sharma, J. E. Atwood, A. K. Jacobson, et al. Amiodarone versus Sotalol for Atrial Fibrillation N. Engl. J. Med., May 5, 2005; 352(18): 1861 - 1872. [Abstract] [Full Text] [PDF]

				M. O'Donnell, G. Agnelli, and J. I. Weitz Emerging therapies for stroke prevention in atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF]

				P. Zimetbaum and M. E. Josephson Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation? Ann Intern Med, November 2, 2004; 141(9): 720 - 726. [Abstract] [Full Text] [PDF]

				T. D. Bahnson and A. O. Grant To Be or Not To Be in Normal Sinus Rhythm: What Do We Really Know? Ann Intern Med, November 2, 2004; 141(9): 727 - 729. [Full Text] [PDF]

				N. van Hemel Quinidine rehabilitated and more lessons from the PAFAC and SOPAT anti-arrhythmic drug trials for the prevention of paroxysmal atrial fibrillation Eur. Heart J., August 2, 2004; 25(16): 1371 - 1373. [Full Text] [PDF]

				Other articles noted Evid. Based Med., May 1, 2004; 9(3): 95 - 96. [Full Text] [PDF]

				K. K Anthony and V. F Mauro Rate Versus Rhythm Control in Atrial Fibrillation Ann. Pharmacother., May 1, 2004; 38(5): 839 - 844. [Abstract] [Full Text] [PDF]

				Guidelines: Management of Newly Detected Atrial Fibrillation Journal Watch Cardiology, February 13, 2004; 2004(213): 3 - 3. [Full Text]

				Management of Patients with Newly Detected Atrial Fibrillation Journal Watch (General), January 27, 2004; 2004(127): 1 - 1. [Full Text]

				V. Snow, K. B. Weiss, M. LeFevre, R. McNamara, E. Bass, L. A. Green, K. Michl, D. K. Owens, J. Susman, D. I. Allen, et al. Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians Ann Intern Med, December 16, 2003; 139(12): 1009 - 1017. [Abstract] [Full Text] [PDF]